[PCSK-9 inhibitors, effects on LDL-C and future implications: What you should know]

Abstract

The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) in 2003 in families with familial hypercholesterolemia (HF) later generated the development of pharmacological strategies in order to inhibit this protein. Twelve years after this discovery, the first two biological compounds (monoclonal antibodies) were approved, which have been shown to substantially decrease LDL-C and other lipid subfractions. The objective of the present article is to review the history of the discovery of PCSK9, its physiology and pathophysiology and subsequent pharmacological development. The objectives and goals reached to date and the pending questions regarding the efficacy and safety of its clinical use are presented.

Keywords: Alirocumab; Evolocumab; Inhibidores proproteína convertasa de subtilisina/kexina tipo 9; Lipoproteína de baja densidad; Low density lipoprotein; Proprotein convertase subtilisin/kexin type 9; Proprotein convertase subtilisin/kexin type 9 Inhibitors; Proproteína convertasa de subtilisina/kexina tipo 9.